Cellectis (CLLS) Competitors $3.98 -0.54 (-11.95%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.09 +0.11 (+2.76%) As of 10/17/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. VALN, PROK, ANAB, KURA, AVBP, PHAT, CRMD, MRVI, VIR, and DNAShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Valneva (VALN), ProKidney (PROK), AnaptysBio (ANAB), Kura Oncology (KURA), ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), CorMedix (CRMD), Maravai LifeSciences (MRVI), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Valneva ProKidney AnaptysBio Kura Oncology ArriVent BioPharma Phathom Pharmaceuticals CorMedix Maravai LifeSciences Vir Biotechnology Ginkgo Bioworks Valneva (NASDAQ:VALN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Is VALN or CLLS more profitable? Valneva has a net margin of -33.87% compared to Cellectis' net margin of -100.69%. Valneva's return on equity of -34.78% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Valneva-33.87% -34.78% -13.43% Cellectis -100.69%-68.05%-21.53% Which has more risk & volatility, VALN or CLLS? Valneva has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500. Do analysts recommend VALN or CLLS? Valneva currently has a consensus target price of $15.00, suggesting a potential upside of 49.09%. Cellectis has a consensus target price of $8.00, suggesting a potential upside of 101.01%. Given Cellectis' higher possible upside, analysts plainly believe Cellectis is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Cellectis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VALN or CLLS? In the previous week, Valneva and Valneva both had 6 articles in the media. Valneva's average media sentiment score of 0.35 beat Cellectis' score of 0.35 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in VALN or CLLS? 11.4% of Valneva shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better valuation & earnings, VALN or CLLS? Valneva has higher revenue and earnings than Cellectis. Valneva is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M4.71-$13.25M-$0.98-10.27Cellectis$49.22MN/A-$36.76M-$0.82-4.85 SummaryValneva beats Cellectis on 8 of the 14 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$251.24M$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.80%P/E Ratio-4.8522.4484.7527.11Price / SalesN/A267.64519.29179.59Price / CashN/A46.5937.1661.22Price / Book1.6910.4112.246.52Net Income-$36.76M-$52.47M$3.33B$276.84M7 Day Performance-1.49%2.32%1.19%1.95%1 Month Performance25.95%11.14%6.18%2.21%1 Year Performance108.38%11.15%59.89%34.06% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis1.9034 of 5 stars$3.98-11.9%$8.00+101.0%+108.4%$251.24M$49.22M-4.85290News CoveragePositive NewsAnalyst ForecastGap UpVALNValneva2.9238 of 5 stars$10.50+1.3%$15.00+42.9%+79.0%$891.07M$183.52M-10.71700Short Interest ↓PROKProKidney2.3685 of 5 stars$2.99-1.0%$6.25+109.0%+50.0%$888.73M$80K-5.253Gap DownANABAnaptysBio2.8787 of 5 stars$32.46+3.5%$52.00+60.2%-1.6%$878.27M$91.28M-7.25100Trending NewsAnalyst ForecastAnalyst RevisionKURAKura Oncology4.1638 of 5 stars$9.93+0.8%$24.10+142.7%-45.6%$854.95M$53.88M-4.39130Gap DownAVBPArriVent BioPharma1.4476 of 5 stars$20.90+0.2%$39.14+87.3%-32.7%$846.27MN/A-5.2040PHATPhathom Pharmaceuticals2.9817 of 5 stars$12.53+6.0%$17.50+39.7%-20.2%$838.55M$55.25M-2.65110News CoverageAnalyst UpgradeCRMDCorMedix3.2918 of 5 stars$10.58-1.4%$18.00+70.1%-3.0%$837.57M$43.47M14.1130MRVIMaravai LifeSciences3.7784 of 5 stars$3.30+3.4%$5.22+58.1%-59.3%$814.60M$259.18M-2.43610News CoverageAnalyst ForecastOptions VolumeVIRVir Biotechnology3.5538 of 5 stars$5.86+1.0%$17.30+195.2%-25.1%$805.72M$74.21M-1.47580News CoverageAnalyst ForecastInsider TradeDNAGinkgo Bioworks1.2548 of 5 stars$13.20-2.4%$9.00-31.8%+58.4%$800.38M$227.04M-2.25640 Related Companies and Tools Related Companies VALN Alternatives PROK Alternatives ANAB Alternatives KURA Alternatives AVBP Alternatives PHAT Alternatives CRMD Alternatives MRVI Alternatives VIR Alternatives DNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
